The Chinese name of Adagraxibu and its domestic manufacturer

The Chinese name of Adagrasib (Adagrasib) is Adagrasib, AdagrasibThe original drug is not on the domestic market, so there are no relevant domestic manufacturers to produce the drug. The clinical research of adagrasib is also ongoing. It is believed that in the near future, adagrasib original drugs or domestic drugs will be developed and sold in China. In the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutations, the effective rate of adagrasib can reach over 42%. At the same time, it can significantly extend the progression-free survival of patients and reduce the risk of tumor progression and death.

Adagrasib inhibits tumor cell growth and viability in cells harboring the KRAS G12C mutation and causes tumor regression with minimal off-target activity in a KRAS G12C-mutated tumor xenograft model. Adagrasiib is not suitable for all patients with non-small cell lung cancer. Only patients with KRAS G12C mutations can use this drug. Therefore, patients need to undergo genetic testing before use to determine whether they are suitable for the drug. In addition, adagrasib also has some side effects, such as nausea, vomiting, diarrhea, fatigue, etc., but its side effects are much milder than traditional chemotherapy drugs.

Sinceadagrasibthe original drug has not yet been launched in China, patients can only purchase adagrasib through overseas channels, and the U.S. original version of 200mg*180 tablets is priced at hundreds of thousands of yuan per box (the price may fluctuate due to exchange rates), which is very expensive. Currently, there are no generic drugs of adagrasib produced overseas. For more drug information and specific prices, please consult Yaode’s medical consultant.